by David Eyre | Sep 6, 2022 | UK
In the case of Neurim and Flynn v Mylan [2022] EWCA Civ 699 The Court of Appeal has issued a decision finding that the plausibility of a therapeutic effect can be demonstrated using subjective data obtained by questioning the users of a pharmaceutical product....
by Juliette Boynton | Aug 12, 2022 | EPO
In an opposition against a patent granted in the name of Canon Kabushiki Kaisha, André Nickel as opponent indicated that the opposition was filed against claims 8 and 9, and not the patent “as a whole”. Argumentation in support of the opposition was provided, this...
by Sean Hutchinson | Aug 1, 2022 | EPO
Background There has recently been an extensive debate surrounding the legal basis for the EPO’s practice of requiring an Applicant of a European patent application to amend the description of the application to bring this into conformity with the allowed claims. This...
by George Schlich | Jul 19, 2022 | EPO
A copy of our Amicus Curiae brief is reproduced below and can be downloaded here: Schlich Amicus Curiae – 18 July 2022. Executive Summary These combined referrals from Board 3.3.04, G1/22 and G2/22, are both headed “Entitlement to priority” [1]. Decision T844/18...
by Alex Bajjon | Jul 7, 2022 | US & International
Excess Claims Fees Up until now, there have been no excess claims fees in Canada and therefore minimal or no incentives for applicants to limit the number of claims in their patent applications. Under the new regime, excess claims fees will be payable for claim sets...
Recent Comments